Increased Expression of FGF19 Contributes to Tumor Progression and Cell Motility of Human Thyroid Cancer

Otolaryngology - Head and Neck Surgery (United States)

Volumn 154, Issue 1, 2016, Pages 52-58

  Zhang, Xiliang ^a   Wang, Zhonghua ^a   Tian, Lei ^a   Xie, Jiangping ^a   Zou, Guijun ^a   Jiang, Futing ^a  

^a NAVY GENERAL HOSPITAL   (China)

Author keywords

fibroblast growth factor 19; immunohistochemistry; motility; small interfering RNA; thyroid cancer

Indexed keywords

FIBROBLAST GROWTH FACTOR 19; SMALL INTERFERING RNA; FGF19 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURGERY; CELL INVASION ASSAY; CELL MIGRATION ASSAY; CELL MOTILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DISTANT METASTASIS; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN LOCALIZATION; RETROSPECTIVE STUDY; THYROID CANCER; THYROID CANCER CELL LINE; THYROIDECTOMY; BIOSYNTHESIS; CELL MOTION; DISEASE COURSE; METABOLISM; MIDDLE AGED; PATHOLOGY; THYROID TUMOR; TUMOR CELL CULTURE;

ADULT; AGED; CELL MOVEMENT; DISEASE PROGRESSION; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84954156198     PISSN: 01945998     EISSN: 10976817     Source Type: Journal    
DOI: 10.1177/0194599815609534     Document Type: Article

References (25)

1. Nguyen QT, Lee EJ, Huang MG, Park YI, Khullar A, Plodkowski RA,. Diagnosis and treatment of patients with thyroid cancer. Am Health Drug Benefits. 2015; 8: 30-40.
2. Krajewska J, Jarzab B,. Novel therapies for thyroid cancer. Expert Opin Pharmacother. 2014; 15: 2641-2652.
3. Wojakowska A, Chekan M, Widlak P, Pietrowska M,. Application of metabolomics in thyroid cancer research. Int J Endocrinol. 2015; 2015: 258763.
4. Alonso-Gordoa T, Díez JJ, Durán M, Grande E,. Advances in thyroid cancer treatment: latest evidence and clinical potential. Ther Adv Med Oncol. 2015; 7: 22-38.
5. Keutgen XM, Sadowski SM, Kebebew E,. Management of anaplastic thyroid cancer. Gland Surg. 2015; 4: 44-51.
6. Wu X, Li Y,. Therapeutic utilities of fibroblast growth factor 19. Expert Opin Ther Targets. 2011; 15: 1307-1316.
7. Schaap FG,. Role of fibroblast growth factor 19 in the control of glucose homeostasis. Curr Opin Clin Nutr Metab Care. 2012; 15: 386-391.
8. Jones S,. Mini-review: endocrine actions of fibroblast growth factor 19. Mol Pharm. 2008; 5: 42-48.
9. Lin BC, Desnoyers LR,. FGF19 and cancer. Adv Exp Med Biol. 2012; 728: 183-194.
10. Zhou M, Wang X, Phung V, et al. Separating tumorigenicity from bile acid regulatory activity for endocrine hormone FGF19. Cancer Res. 2014; 74: 3306-3316.
11. Miura S, Mitsuhashi N, Shimizu H, et al. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer. 2012; 12: 56.
12. Hyeon J, Ahn S, Lee JJ, Song DH, Park CK,. Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma. Dig Dis Sci. 2013; 58: 1916-1922.
13. Buhmeida A, Dallol A, Merdad A, et al. High fibroblast growth factor 19 (FGF19) expression predicts worse prognosis in invasive ductal carcinoma of breast. Tumour Biol. 2014; 35: 2817-2824.
14. Nagamatsu H, Teishima J, Goto K, et al. FGF19 promotes progression of prostate cancer. Prostate. 2015; 75: 1092-1101.
15. Jiang SS, Weng DS, Wang QJ, et al. Galectin-3 is associated with a poor prognosis in primary hepatocellular carcinoma. J Transl Med. 2014; 12: 273.
16. Cao Z, Fu B, Deng B, Zeng Y, Wan X, Qu L,. Overexpression of Chemokine (C-X-C) ligand 1 (CXCL1) associated with tumor progression and poor prognosis in hepatocellular carcinoma. Cancer Cell Int. 2014; 14: 86.
17. Remmele W, Stegner HE,. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987; 8: 138-140.
18. Mellor HR,. Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations. Liver Int. 2014; 34: e1-e9.
19. Feng S, Dakhova O, Creighton CJ, Ittmann M,. Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression. Cancer Res. 2013; 73: 2551-2562.
20. Lemieux SM, Hadden MK,. Targeting the fibroblast growth factor receptors for the treatment of cancer. Anticancer Agents Med Chem. 2013; 13: 748-761.
21. Sawey ET, Chanrion M, Cai C, et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell. 2011; 19: 347-358.
22. Beenken A, Mohammadi M,. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009; 8: 235-253.
23. Wu X, Li Y,. Understanding the structure-function relationship between FGF19 and its mitogenic and metabolic activities. Adv Exp Med Biol. 2012; 728: 195-213.
24. Falvella FS, Frullanti E, Galvan A, et al. FGFR4 Gly388Arg polymorphism may affect the clinical stage of patients with lung cancer by modulating the transcriptional profile of normal lung. Int J Cancer. 2009; 124: 2880-2885.
25. Desnoyers LR, Pai R, Ferrando RE, et al. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene. 2008; 27: 85-97.